Lv2
139 积分 2023-02-16 加入
The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs
20小时前
待确认
Unravelling the GIPR agonist versus antagonist paradox
21小时前
已完结
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
1个月前
已完结
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
1个月前
已完结
Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms
2个月前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
2个月前
已完结
Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice
2个月前
已完结
GLP-1R agonists protect against Alzheimer’s disease by rewiring energy regulation
2个月前
已完结
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study
4个月前
已完结
Assessing the clinical progress of the bispecific nanobody sonelokimab
4个月前
已完结
皖公网安备34019202002308
